HSBC Holdings’s Revolution Medicines RVMD Stock Holding History

HSBC Holdings’s Portfolio RVMD Stock Details RVMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.19M	Buy	32,791 +29,953	+1,055%	+$3.02M	﹤0.01%	1331
2025 Q4	$227K	Sell	2,838 -185,359	-98%	-$12.2M	﹤0.01%	2646
2025 Q3	$8.78M	Sell	188,197 -43,688	-19%	-$1.71M	﹤0.01%	975
2025 Q2	$8.53M	Buy	231,885 +11,697	+5%	+$449K	0.01%	952
2025 Q1	$7.78M	Sell	220,188 -49,106	-18%	-$1.99M	﹤0.01%	970
2024 Q4	$11.8M	Sell	269,294 -11,328	-4%	-$572K	0.01%	887
2024 Q3	$12.7M	Buy	280,622 +265,709	+1,782%	+$11.6M	0.01%	849
2024 Q2	$567K	Sell	14,913 -152,236	-91%	-$5.69M	﹤0.01%	1914
2024 Q1	$5.38M	Buy	+167,149	New	+$4.95M	﹤0.01%	1081
2022 Q4	–	Sell	-10,134	Closed	-$204K	–	3178
2022 Q3	$204K	Buy	+10,134	New	+$223K	﹤0.01%	2624
2020 Q2	–	Sell	-10,655	Closed	-$229K	–	2831
2020 Q1	$229K	Buy	+10,655	New	+$295K	﹤0.01%	2212

Other funds holding RVMD

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

HSBC Holdings's RVMD Position: Q1 2026 in Review

HSBC Holdings increased its Revolution Medicines (RVMD) stake by 1,055% in Q1 2026, buying an estimated $3.02M and bringing the position to 32,791 shares worth $3.19M. The position accounts for ﹤0.01% of the portfolio, ranked #1331.

HSBC Holdings first reported a position in RVMD in Q1 2020 and has held it in 11 quarters since. The position peaked at $12.7M in Q3 2024. 512 funds tracked by Wall St. Rank hold RVMD as of Q1 2026.

HSBC Holdings held 32,791 shares of Revolution Medicines worth $3.19M as of Q1 2026.
HSBC Holdings bought 29,953 Revolution Medicines shares in Q1 2026, an estimated $3.02M.
Revolution Medicines made up ﹤0.01% of HSBC Holdings's portfolio in Q1 2026, its #1331 holding.
HSBC Holdings first reported a position in Revolution Medicines in Q1 2020 and has held it in 11 quarters since.
HSBC Holdings's Revolution Medicines position peaked at $12.7M in Q3 2024.
512 funds tracked by Wall St. Rank held Revolution Medicines as of Q1 2026.

Based on HSBC Holdings's 13F filing for Q1 2026, filed 30 Apr 2026.